POCT (point-of-care) tumor marker testing is a rapid, patient-directed approach. It holds significant value for cancer prevention, diagnosis, treatment, and monitoring. Its significance lies in the following aspects:
1. Rapid Assisted Screening and Early Diagnosis
Traditional testing is time-consuming, but the Poctell AFS-1000 Quantum Dot POCT analyzer delivers results in 10-15 minutes, providing preliminary screening for high-risk individuals. Its comprehensive coverage of tumor markers, including CEA test kit (25 tests per kit box), AFP test kit, and tPSA test kit, facilitates regular screening and helps detect early signs of cancer through convenient testing.
2. Assists in Real-Time Monitoring of Treatment Effectiveness
This instrument can rapidly detect changes in tumor markers during treatment, helping physicians assess the effectiveness of treatment plans and adjust strategies. Testing can be performed in outpatient clinics and community settings, reducing travel time for patients and improving compliance.
3. Timely Warning of Recurrence and Metastasis
With its rapid testing capabilities, patients can detect signs of recurrence or metastasis early during follow-up, indicating abnormally elevated marker levels, saving time for further testing. Its convenience also facilitates long-term monitoring of patients in recovery.
4. Improving Access to Medical Resources
In settings with limited medical resources, such as primary care hospitals and community settings, the POCTELL AFS-1000 Quantum Dot POCT analyzer requires only simple equipment, such as reagent test cartridges and an analyzer, and can be operated without specialized personnel. This lowers the barrier to entry for testing, allowing patients in remote locations or with limited mobility to access timely testing.
In short, the POCTELL AFS-1000 Quantum Dot POCT analyzer provides patients with a timely and comprehensive testing platform, significantly aiding in early cancer diagnosis and symptom monitoring.